PHARMACEUTICAL CAPSULES

ACGcaps™ GI





A gelatin capsule for dry powder inhalation.

Developed specifically for use with sustainable (no propellant) dry powder inhalation devices and a wide range of formulations, ACGcaps™ GI ensures accurate dosing, uniform dispersion, and efficient delivery to the respiratory system, enhancing drug effectiveness and patient outcomes.

Key features

- / Low powder retention for maximum dose delivery
- / Proven puncturing, cutting and twist-open performance
- / Compatible with several dry powder inhalation devices
- / Suitable for a wide range of active pharmaceutical ingredients
- / Proven machine-friendly design
- / Complies with stringent regulatory requirements for microbiological limits



Technical specifications


- / Powder retention: not more than 1.0%
- / Moisture content: 13.0% to 16.0%
- / Microbial limit: not more than 100 CFU

Low powder retention ensures effective API delivery.

ACGcaps™ GR and ACGcaps™ GI were carefully filled with the same powder and their surfaces examined under a scanning electron microscope.

The microscopic image of ACGcaps™ GR shows extensive powder adhesion and accumulation on its surface, forming distinct clusters and patches. In contrast, the surface of ACGaps™ GI appears smoother and cleaner, and revealing minimal powder retention on its surface. This ensures that dry powder formulations will be effectively delivered to the lungs.

EM magnification



ACGaps™ GI

ACGaps™ GR



This certification is applicable to certain colours and / or variants.

